高血压是导致脑卒中和冠心病的主要危险因素。我们在国际上率先研制出人血管紧张素1型受体（AT1R）靶向降压疫苗（ATRQβ-001降压疫苗），该疫苗不仅有效降压，而且具有极优良的靶器官保护作用，深入研究ATRQβ-001疫苗对高血压阻力血管的保护机制具有重要意义。我们拟研究：ATRQβ-001疫苗通过APJ-AT1R异二聚化激活APJ通路，并正向调节ACE2-Ang(1-7)-MasR轴，削弱血管重构效应通路，从而发挥血管保护作用，为具有自主知识产权的ATRQβ-001降压疫苗的药理学提供全新的理论依据。

Hypertension is the most important risk factor of stroke and coronary heart disease. It is of great significance to further study mechanism of vascular remodeling in hypertension and look for new treatment technology. We invented the angiotensin II receptor type 1 (AT1R) hypertension vaccine (ATRQβ-001 vaccine). The ATRQβ-001 vaccine signifcantly decreased the blood pressure of hypertensive animals and prevented remodeling of vulnerable hypertensive target organs. This project will study the protective mechanism of ATRQβ-001 vaccine on vascular remodeling. We hypothesized: ATRQβ-001 vaccine activates APJ pathway through promoting the heterodimerization of AT1R/APJ, and positively regulates ACE2-Ang (1-7)-MasR axis, which weaken the effect of vascular remodeling pathway and play a significant role in the vascular protection.